Close
  Indian J Med Microbiol
 

Figure 1: CHRM1 expression is upregulated in the early stages of prostate cancer. Representative images of immunohistochemical staining of CHRM1 in human prostate cancer tissue arrays: (a) stage I patient, (b) stage II patient, (c) stage III patient, and (d) stage IV patient tissue samples are shown. Note that CHRM1 is widely expressed in human prostate cancer tissues and mainly localized in glandular epithelium. Scale bars = 100 μ m. (e) Quantification of CHRM1 staining intensities in early-stage (I–II, n = 34) and late-stage (III–IV, n = 26) prostate adenocarcinomas. (f) Quantification of CHRM1 staining intensities in nonmetastatic (n = 50) and metastatic (n = 10) prostate adenocarcinomas. CHRM1: muscarinic acetylcholine receptor M1.

Figure 1: CHRM1 expression is upregulated in the early stages of prostate cancer. Representative images of immunohistochemical staining of CHRM1 in human prostate cancer tissue arrays: (<b>a</b>) stage I patient, (<b>b</b>) stage II patient, (<b>c</b>) stage III patient, and (<b>d</b>) stage IV patient tissue samples are shown. Note that CHRM1 is widely expressed in human prostate cancer tissues and mainly localized in glandular epithelium. Scale bars = 100 μ m. (<b>e</b>) Quantification of CHRM1 staining intensities in early-stage (I–II, <i>n</i> = 34) and late-stage (III–IV, <i>n</i> = 26) prostate adenocarcinomas. (f) Quantification of CHRM1 staining intensities in nonmetastatic (<i>n</i> = 50) and metastatic (<i>n</i> = 10) prostate adenocarcinomas. CHRM1: muscarinic acetylcholine receptor M1.